News Conference News ACC 2026 Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE Yael L. Maxwell March 28, 2026
Presentation ACC 2026 Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease: The Ez-PAVE randomized clinical trial Presenter: Byeong-Keuk Kim March 28, 2026
News Daily News Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy Todd Neale July 20, 2022